GGrantIndex
Sort

261,768 grants matching gene therapy

Deciphering the physiological role and interplay between ubiquitination and phosphorylation pathways to guide targeted cancer therapies

$1,025,412
Wenyi Wei · Beth Israel Deaconess Medical Center · R35 · FY2022 · CA

A multi-faceted approach to identifying K-Ras synthetic lethal relationships

$1,025,393
Kevin Michael Haigis · Beth Israel Deaconess Medical Center · U01 · FY2016 · CA

A Haplotype Map for Multiple Sclerosis

$1,025,276
Stephen L Hauser · University Of California, San Francisco · R01 · FY2011 · NS

Molecular Analysis Of Retroviral Genes And Their Products

$1,025,169
Klaus Strebel · National Institute Of Allergy And Infectious Diseases · ZIA · FY2012 · AI

Targeting FGFR4, RAS, and PAX3-FOXO1 gene in Rhabdomyosarcoma

$1,025,166
Javed Khan · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

Biomarker and Phenotypic Risk Factors for Breast Cancer Lymphedema

$1,025,118
Christine A. Miaskowski · University Of California, San Francisco · R01 · FY2017 · CA

PROgression of Tuberculosis infECTion in young children living with and without HIV: the PROTECT study

$1,025,117
Adithya Cattamanchi · University Of California-Irvine · R01 · FY2024 · AI

A molecular toolbox to accelerate drug development for histone lysine methylation regulators

$1,025,085
Jonathan Michael Burg · Epicypher, Inc. · R44 · FY2022 · TR

A molecular toolbox to accelerate drug development for histone lysine methylation regulators

$1,025,085
Jonathan Michael Burg · Epicypher, Inc. · R44 · FY2023 · TR

Insulin Producing Cells from Amniotic Stem Cells for Diabetes Therapy

$1,025,080
Anthony Atala · Wake Forest University Health Sciences · R01 · FY2009 · EB

Insulin Producing Cells from Amniotic Stem Cells for Diabetes Therapy

$1,025,080
Anthony Atala · Wake Forest University Health Sciences · R01 · FY2008 · EB

Arylsulfonamides for the Treatment of Primary and Metastatic Uveal Melanoma

$1,025,001
Margaret Kenny Offermann · Oncospherix, Inc. · R44 · FY2024 · CA

Arylsulfonamides for the Treatment of Primary and Metastatic Uveal Melanoma

$1,024,999
Margaret Kenny Offermann · Oncospherix, Inc. · R44 · FY2023 · CA

Molecular, Cellular and Genetic Analyses of Malignancies Associated with NF1

$1,024,981
Karlyne M Reilly · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA

Intratumoral immunotherapy with formulated resiquimod for metastatic melanoma

$1,024,973
Yen Tun Wang · Curebiotech, Inc. · R44 · FY2019 · CA

IND-enabling development for IN-003, an inhaled mAb therapy against human metapneumovirus infection

$1,024,942
Jeff T Hutchins · Inhalon Biopharma, Inc. · R44 · FY2024 · AI

DNA Replication, Cancer and Chemotherapy

$1,024,926
Melvin Depamphilis · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2022 · HD

IND-enabling development for IN-003, an inhaled mAb therapy against human metapneumovirus infection

$1,024,879
Jeff T Hutchins · Inhalon Biopharma, Inc. · R44 · FY2025 · AI

Molecular Mechanisms and Applications of Novel ER/GPER-selective Ligands

$1,024,823
Eric R Prossnitz · University Of New Mexico Health Scis Ctr · R01 · FY2025 · CA

Metrifonate local application for DFU treatment

$1,024,812
Mark Allan Tepper · Epoulosis Therapeutics, Inc. · R44 · FY2025 · DK

Engineering a Human Microphysiological System for the Characterization of Islet-Immune Interactions

$1,024,766
Cherie L Stabler · University Of Florida · UG3 · FY2020 · DK

Allogeneic Hematopoietic Transplantation for Primary Immunodeficiency Diseases

$1,024,731
Dennis Hickstein · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

Pilot trial of dronabinol adjunctive treatment of agitation in Alzheimer's disease (AD)

$1,024,654
Paul B Rosenberg · Johns Hopkins University · R01 · FY2016 · AG

Spatially-resolved protein and transcriptome mapping of senescent cells

$1,024,647
Marissa Joy Schafer · Mayo Clinic Rochester · UH3 · FY2025 · CA

Non-cytotoxic augmentation of fetal hemoglobin and bone marrow reserves

$1,024,639
Yogen Saunthararajah · University Of Michigan At Ann Arbor · P01 · FY2021 · HL